MHRA and REC approved CTA for Ph 1 ZIMA-101 trial of ZI-MA4-1 in patients with advanced solid cancers February 25, 2026
FDA Clears IND Application for CS2009 (PD-1/VEGF/CTLA-4) to Advance into Ph 2 Clinical Trial February 25, 2026
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors February 17, 2026
CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in China February 17, 2026
First Patient Enrolled in Global Ph 1 Trial of AN9025 for Solid Tumors Harboring RAS Mutations February 17, 2026
FDA cleared IND application for NPX372 in B7-H7–expressing solid tumors, including lung adenocarcinoma, RCC, and pancreatic adenocarcinoma February 17, 2026
FDA clears IND application for Ph 1 study of GTB-5550 TriKE for Solid Tumors Expressing B7-H3 February 9, 2026
FDA clears IND application for Ph 1 study of N17350 in patients with advanced solid tumors February 9, 2026
Multiple Sites Activated for Ph 1b/2 Trial of AMXT 1501 and DFMO in Patients with solid tumors including Breast Cancer and Melanoma February 9, 2026
First Patient Dosed in Ph 1a/2a Trial of DPTX3186 in Advanced Solid Tumors, Focused on Gastric Cancer February 9, 2026
AstraZeneca announced $15B investment in China through 2030 to expand medicines manufacturing and R&D February 1, 2026
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Gen Bi-and Multi-Functional Fusion Protein Pipeline February 1, 2026
Key Patent Filed and Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors Unveiled February 1, 2026
Eikon Therapeutics Secures $350.7M Series D to Advance Clinical-Stage Programs and Future Pipeline February 1, 2026
First Patient Dosed in Ph 1 Trial of RMC-5127 in patients with RAS G12V–mutated solid tumors February 1, 2026
Janux Therapeutics and Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors January 25, 2026
Ph 1/2 Program Initiated for Elraglusib in refractory melanoma and additional target solid tumor and heme cancers January 25, 2026
MediLink Therapeutics and Roche to develop and commercialize YL201 across numerous solid tumor types January 18, 2026
